Viking Therapeutics: High-Risk, High-Reward Play
Update: 2025-12-29
Description
Viking Therapeutics, a biotech company valued at $4.2 billion, is making strides in obesity treatments with its lead drug, VK2735. Targeting GLP-one and GIP receptors, VK2735 is being tested in phase three trials for obese individuals and those with type two diabetes. The company aims to complete enrolling patients by the end of 2025 and early 2026, respectively. Despite posting significant losses, Viking Therapeutics has a solid cash position of $715 million, which should cover phase three trials without additional funding. Analysts predict a strong buy, with a potential upside of 141% to an average target price of $89.82. Key events in 2026 could drive significant stock movements. Checkout Solipillow.com
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
